Satellos Bioscience (NASDAQ:MSLE) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Satellos Bioscience (NASDAQ:MSLE) to a strong sell rating in a report published on Saturday.

Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald started coverage on shares of Satellos Bioscience in a report on Wednesday. They set an “overweight” rating on the stock. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Finally, Weiss Ratings started coverage on Satellos Bioscience in a research report on Wednesday, February 11th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Satellos Bioscience Trading Down 6.5%

Shares of MSLE opened at $8.00 on Friday. The company has a market cap of $123.68 million, a P/E ratio of -6.66 and a beta of 1.10. Satellos Bioscience has a 52 week low of $4.53 and a 52 week high of $13.39.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.